AstraZeneca invests $30 million to upgrade production and supply base in China
By Pang Bo | chinadaily.com.cn | Updated: 2026-09-17 17:22
AstraZeneca unveiled an investment of nearly 200 million yuan ($29.81 million) to upgrade its production and supply base in Wuxi, China, the company's Chinese unit said in a statement on Thursday.
The upgraded facility will be used for development and production of AstraZeneca's innovative cardiovascular drugs.
Covering a construction area of approximately 5,800 square meters, the project is scheduled to become operational in the fourth quarter of 2029 with an estimated annual capacity of 400 million tablets.
Editor's Pick
